Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1432P - Incorporating psycho-social factors in cancer treatment adverse events studies

Date

10 Sep 2022

Session

Poster session 04

Topics

Psychosocial Aspects of Cancer

Tumour Site

Presenters

Chiara Casini

Citation

Annals of Oncology (2022) 33 (suppl_7): S653-S659. 10.1016/annonc/annonc1071

Authors

C. Casini1, D. Monzani2, M. Masiero2, K. Mazzocco3, R. Grasso2, D. Fotiadis4, N. Memos5, K. KERAMIDA6, G. Curigliano1, C. Cipolla7, D. Cardinale8, A. Papakonstantinou9, A. Constantinidou10, C. Conti11, G. Pravettoni1

Author affiliations

  • 1 Experimental Oncology, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 2 Experimental Oncology, University of Milan, 20122 - Milan/IT
  • 3 Department Of Oncology And Hematoncology - Università Degli Studi Di Milano, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 4 Experimental Oncology, UOI - University of Ioannina, 45110 - Ioannina/GR
  • 5 Sarcoma And Melanoma Department, Aretaieio Hospital, 2024 - Strovolos/CY
  • 6 Cardiology, Cardio-oncology Clinic, Attikon University Hospital, 124 62 - Haidari/GR
  • 7 Cardiology, Cardio-oncology Clinic, European Institute of Oncology, 20132 - Milan/IT
  • 8 Cardiology, Cardio-oncology Clinic, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 9 Oncology Department, Karolinska University Hospital-Solna, 171 76 - Solna/SE
  • 10 Medical Oncology Department, Bank of Cyprus Oncology Centre, 2006 - Nicosia/CY
  • 11 -, IMS – Istituto di Management Sanitario, Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1432P

Background

Cancer patients and survivors dealing with adverse events due to cancer treatment, experience impairments in their overall quality of life. In particular, literature reports the potential cardiotoxic effects of cancer therapies, clinically observable up to 10 years after the completion of interventions. However, even though associations between psycho-social factors and cardiovascular diseases have been appreciated in literature, less attention has been given to psycho-social features as correlates of cancer treatment adverse events.

Methods

To address this gap in literature, we completed a two-round Delphi consensus study in order to obtain an expert consensus regarding which psycho-social variables may be linked to cancer treatment adverse events. First, through a literature narrative review, we identified 23 psychosocial constructs related to cardiovascular diseases. Then, a panel of experts, consisting of 32 researchers and professionals in the field of psycho-oncology, clinical and health psychology and oncology, were invited via email to participate in the online Delphi consensus procedure. Participants were asked to rate their level of agreement on considering and measuring the selected constructs on a 5-point Likert scale, to give reasons for their evaluations, and finally to suggest any further variable.

Results

Coming from the two-round Delphi consensus study have suggested the importance of considering fifteen psychological constructs such as anxiety, caregiver burden, cognitive impairment, depression, distress, fatigue, generalized anxiety disorder, loneliness, perceived social support, perceived stress, quality of life, self-control and self-management, stressful life events, self-efficacy, and resilience. Perceived stress and distress were the variables showing the highest level of consensus.

Conclusions

Psycho-social factors may have an impact on adjustment and self-management of cancer treatment adverse events; in particular perceived stress is considered to play a key role. Further studies in this direction are crucial to better investigate direct and indirect links of these psychological constructs with the management of treatment-related adverse events.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

CARDIOCARE European Project, a HORIZON2020 funded project (Grant agreement ID: 945175).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.